KING OF PRUSSIA, Pa. and CARY, N.C., June 25, 2024 /PRNewswire/ -- United BioSource LLC (UBC), a leading provider of evidence development solutions, and Thread®, a leading decentralized research, electronic clinical outcome assessment (eCOA) and consulting services provider, today announced the expansion of their SitePlus solution. This joint offering, the outcome of a successful six-year working relationship, has provided early recruitment and retention success for biopharma customers since its March 2023 launch. UBC and Thread have now expanded the solution to offer additional central site services and technology features for both post-approval research and Phase II/III interventional clinical trials.
BRISBANE, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living...
LONDON, June 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced...
A maker of health education podcasts—including installments sponsored by major biopharma and medtech players—is adding a subscription model to power future development of even more audio content.
14-month data show treatment with setrusumab resulted in a large, sustained 67% reduction in annualized fracture rate and persistent median annualized fracture rate of 0.00 (p=0.0014) Treatment...
Biopharma investment trends continue to shift, with venture funding jumping to $7.4 billion across 188 deals for the first quarter of the year. This compares to $6.3 billion across 248 deals the previous quarter and demonstrates an increase in deal value despite declining deal count, according to PitchBook.
BPGbio Appoints Biopharma Industry Leader Scott Minick to Board of Directors
WASHINGTON, D.C. / ACCESSWIRE / May 13, 2024 / During a recent congressional hearing, Director Anne Milligram of the Drug Enforcement Administration (DEA) passionately addressed the alarming surge in illegal fentanyl-related deaths across the nation. Her plea for action against this epidemic resonated widely. However, amidst this urgency, a significant contradiction emerges - the DEA's hindrance of psychedelic research and drug development.
Redwire Pioneering Biopharma Production in Space by Successfully Bioprinting Live Human Heart Tissue and Delivering Second Batch of PIL-BOX Pharmaceutical Crystal Experiments